Johnson & Johnson MedTech has announced significant advancements in its pulsed field ablation (PFA) technology for treating atrial fibrillation (AF). During the joint annual meeting of the Asia Pacific Heart Rhythm Society (APHRS) and the Japanese Heart Rhythm Society (JHRS) in Yokohama, Japan, from November 12 to 15, 2025, the company will present new clinical and real-world data from its VARIPULSE™ Platform.
This fully integrated platform consists of the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System, all designed to enhance procedural outcomes. The VARIPULSE™ Platform is currently approved for use across the United States, Europe, Asia Pacific, Canada, and Latin America, with over 25,000 procedures conducted worldwide.
Jing Li, Vice President of Electrophysiology & Neurovascular at Johnson & Johnson MedTech, emphasized the company’s commitment to advancing scientific knowledge. “The clinical evidence we’re presenting at this year’s APHRS and JHRS reflects our dedication and the comprehensive strength of our leading portfolio for atrial fibrillation and complex arrhythmias,” Li stated.
Key Presentations Highlighting Safety and Efficacy
The presentations at the conference will cover various aspects of the VARIPULSE™ Platform, focusing on safety, efficacy, and workflow improvements. Notable sessions include:
– The QUEST AF trial, which will offer an oral presentation on the acute success of persistent atrial fibrillation ablation using a temperature-controlled, very high-power short-duration radiofrequency catheter.
– A poster presentation from the VARIPURE (SECURE) study, detailing the real-world workflow and efficiency of a novel pulsed field ablation variable loop circular catheter.
– Insights from the admIRE trial regarding age and diagnosis-to-ablation time effects on sex differences in 12-month outcomes after catheter ablation.
Other significant discussions will focus on procedural characteristics and the clinical outcomes of same-day discharge following pulsed field ablation treatment for atrial fibrillation.
Commitment to Patient-Centric Innovation
Johnson & Johnson MedTech aims to further collaborate with the clinical community to generate more real-world evidence surrounding the VARIPULSE™ Platform. This effort is part of the company’s broader mission to address complex health challenges, particularly in cardiovascular care.
The comprehensive series of symposia, hands-on demonstrations, and educational sessions planned for the APHRS and JHRS events will provide healthcare professionals with valuable insights into the latest advancements in atrial fibrillation treatment.
With a robust cardiovascular portfolio that includes advanced mapping and navigation technologies, Johnson & Johnson continues to position itself as a leader in the treatment of heart rhythm disorders. The company remains dedicated to innovating solutions that are not only effective but also tailored to meet the needs of patients worldwide.
For more information on Johnson & Johnson MedTech’s initiatives and innovations, visit their official website.
